GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Cyclically Adjusted Price-to-FCF

MedMira (MedMira) Cyclically Adjusted Price-to-FCF : (As of May. 22, 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


MedMira Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for MedMira's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Cyclically Adjusted Price-to-FCF Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MedMira's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, MedMira's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where MedMira's Cyclically Adjusted Price-to-FCF falls into.



MedMira Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

MedMira's Cyclically Adjusted FCF per Share for the quarter that ended in Jan. 2024 is calculated as:

For example, MedMira's adjusted Free Cash Flow per Share data for the three months ended in Jan. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.001/125.0724*125.0724
=-0.001

Current CPI (Jan. 2024) = 125.0724.

MedMira Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201404 -0.003 98.920 -0.004
201407 -0.001 99.315 -0.001
201410 -0.001 99.473 -0.001
201501 -0.001 98.209 -0.001
201504 -0.001 99.710 -0.001
201507 -0.001 100.579 -0.001
201510 -0.002 100.500 -0.002
201601 -0.001 100.184 -0.001
201604 -0.001 101.370 -0.001
201607 0.000 101.844 0.000
201610 -0.001 102.002 -0.001
201701 -0.001 102.318 -0.001
201704 0.000 103.029 0.000
201707 0.000 103.029 0.000
201710 -0.001 103.424 -0.001
201801 0.000 104.056 0.000
201804 0.000 105.320 0.000
201807 0.000 106.110 0.000
201810 0.000 105.952 0.000
201901 0.000 105.557 0.000
201904 0.000 107.453 0.000
201907 0.000 108.243 0.000
201910 0.000 107.927 0.000
202001 0.000 108.085 0.000
202004 0.000 107.216 0.000
202007 0.000 108.401 0.000
202010 0.000 108.638 0.000
202101 0.000 109.192 0.000
202104 0.000 110.851 0.000
202107 -0.001 112.431 -0.001
202110 -0.001 113.695 -0.001
202201 -0.001 114.801 -0.001
202204 0.000 118.357 0.000
202207 0.000 120.964 0.000
202210 0.000 121.517 0.000
202301 0.000 121.596 0.000
202304 -0.001 123.571 -0.001
202307 0.000 124.914 0.000
202310 -0.001 125.310 -0.001
202401 -0.001 125.072 -0.001

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MedMira  (OTCPK:MMIRF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


MedMira Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of MedMira's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Industry
Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira Reports FY2021 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 12-01-2021

Management Cease Trade Order Update

By GlobeNewswire GlobeNewswire 12-26-2018

MedMira Closes New Equity Investment for Future Growth

By GlobeNewswire GlobeNewswire 07-15-2021

MedMira Reports First Quarter Results FY2020

By GlobeNewswire GlobeNewswire 12-31-2019

MedMira Reports Third Quarter Results FY2021

By GlobeNewswire GlobeNewswire 06-30-2021

MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

By ACCESSWIRE ACCESSWIRE 01-11-2023

MedMira Reports Third Quarter Results

By GlobeNewswire GlobeNewswire 06-30-2018

MedMira Reports Third Quarter Results FY2023

By ACCESSWIRE 06-30-2023